The Division of Gastroenterology, Hepatology & Nutrition at Children’s Hospital of Philadelphia (CHOP) is pleased to join the North American Society for Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN) at its 2024 Annual Meeting Nov. 6-9, in Hollywood, Florida. 

CHOP is the nation’s first hospital devoted exclusively to the care of children. Since our start in 1855, CHOP has been the birthplace for countless breakthroughs and dramatic firsts in pediatric medicine. CHOP – and its GI Division – have repeatedly earned a spot of the U.S. News & World Report’s Honor Roll of the nation’s best children’s hospitals. 

Leading CHOP at this year’s conference will be Binita M. Kamath, MBBChir, MRCP, MTR, our new Division Chief of Gastroenterology, Hepatology and Nutrition. Dr. Kamath joined CHOP on June 1, 2024, after serving as Interim Head of the Division of Gastroenterology, Hepatology and Nutrition at the Hospital for Sick Children in Toronto, Ontario, Canada. An international leader and world-renowned expert in pediatric hepatology, Dr. Kamath has a special focus on liver disorders in children. View a Q&A with Dr. Kamath. 

Dr. Kamath and the entire Divisional team are thrilled to represent CHOP at NASPGHAN.  

This year, division staff will be participating as session speakers, poster presenters and exhibitors.  

This page will give you all the details you need to know about CHOP at NASPGHAN and well as how you can stay connected with CHOP and access CHOP’s numerous professional resources.

CHOP live presentations at NASPGHAN

Wednesday, Nov. 6: NASPGHAN Single Topic Symposium

7-7:45 a.m. - Morning mentorship with NIAD & CEGIR researchers: Career planning and mentorship small groups *Non-CME/MOC session 

      Panelist: Amanda Muir, MD, MTR  

8:15 a.m. - “Historical perspective of EoE and non-EoE EGIDs” 

     Speaker: Chris A. Liacouras, MD 

12:30 p.m. - Concurrent Lunch Sessions 

• “The who, why and when of recent advances in EGID monitoring” 

         Speaker: Matthew J. Ryan, MD 

• Ask the expert: Case-based discussion on EoE therapies (Group 1) 

         Speaker: Amanda Muir, MD, MTR 

Thursday, Nov. 7: Postgraduate Course

11 a.m.-noon - AM Module 3: Endoscopy 

       Moderator: Lisa Fahey, MD 

2:40-4 p.m. - PM Module 5: Nutrition/potpourri 

2:40 p.m. - “When the lymph isn’t flowing: Management of lymphatic disorders,” by Jefferson Naylor Brownell, MD, MS 

Thursday, Nov. 7: NASPGHAN Annual Meeting

4-5 p.m. - Third Annual NASPGHAN Baby Shark Tank Competition 

Friday, Nov. 8: NASPGHAN Annual Meeting

7-8 a.m. - Meet the Professor Breakfasts

• (Group 4) “Very early onset inflammatory bowel disease” by Trusha Patel, MD

10:30 a.m.-noon - Concurrent Session I 

11:32 a.m. - Live(r) long and prosper: Guidelines and advances in care: “Microbially-derived volatile metabolites in pediatric non-alcoholic fatty liver disease,” by Sarah Abu-Alreesh, MBBS (NASPGHAN Foundation/Abbott Nutrition Advanced Fellowship Training in Pediatric Nutrition) 

2:30-4 p.m. - Concurrent Session II 

2:55 p.m. - “Adenosine supports epithelial homeostasis in eosinophilic esophagitis,” by Amanda Muir, MD, MTR (NASPGHAN Foundation/AstraZeneca Award for Disorders of the Upper Gastrointestinal Tract) 

Saturday, Nov. 9: NASPGHAN Annual Meeting

8:30-10 a.m. - Concurrent Session III 

9:32 a.m. - “Neuroimmune Crosstalk in the Gut: ENS, Immune and Microbial Axes” 

     Moderator: Naomi E. Butler Tjaden, MD, PhD 

2-3 p.m. - Concurrent Session V 

• Motility Skills Workshop: Gut Neurostimulation: Auricular Percutaneous Electrical Nerve Field Stimulation: Hands on Practical Techniques and Clinical Insights 
• “Gastric Pacing,” by Hayat Mousa, MD 

3:02 p.m. - “CBT/Psychological Aspects of Behavioral Changes: Multiple Markers of Success: Interdisciplinary Treatment of MASLD and Obesity,” by E. Thomaseo Burton, PhD, MPH, ABPP 

3:45 p.m. - Concurrent Session VI 

• Beyond the Belly: Integrative Approach to Decoding DGBI (Panel Discussion) 

       Panelist: Jennifer Webster, DO 

CHOP poster presentations at NASPGHAN

Poster Session I: 5-7 p.m. Thursday, Nov. 7 

42. Systemic analysis of patient-derived esophageal epithelial organoid model reveals cell state heterogeneity with conservation of differentiation hierarchy.  

118. Intensified infliximab dosing for pediatric inflammatory bowel disease leads to increased drug exposure, improved clinical outcomes, and has become nearly universal. 

127. Escalated infliximab dosing and frequency with use of therapeutic drug monitoring in very early onset inflammatory bowel disease patients.  

132. Durable immune response and long-term efficacy of COVID-19 vaccination in children with inflammatory bowel disease.  

164. Lightening the load: Utilizing telehealth to ease EHR message burden for physicians. 

179. Severe C. difficile infection in pediatrics: More common than you think. 

220. Body surface gastric mapping improves patient phenotyping for pediatric patients with gastroparesis and functional dyspepsia. 

221. Novel magnetic neurostimulation in pediatric anorectal disorders: Single center experience. 

224. The effect of intrapyloric Botox injection on gastric myoelectrical activity is associated with symptoms improvement in children. 

225. Neuropathic gastroduodenal disorders can be diagnosed by the non-invasive high resolution body surface gastric mapping: A comparison study with antroduodenal manometry. 

231. Fiber in metabolic dysfunction-associated steatotic liver disease: the Find study. 

247. Feasibility and acceptability of the Cellie Coping Kit for children with gastroparesis. 

253. Variation in referral to behavioral health for behavioral treatment of rumination. 

254. Biopsychosocial treatment for pediatric patients with co-morbid GI diagnosis and ARFID. 

Posters During Plenary Session: 8-10 a.m., Friday, Nov. 8 

258. Dose dependent effect of sevoflurane on the esophageal contractile response by functional lumen imaging probe panometry.   

Concurrent Sessions: 10:30 a.m.-noon, Friday, Nov. 8 

262. Annual depression and anxiety screening integrated within IBD clinical care in a large outpatient GI center. 

Poster Sessions II: Noon-2 p.m. Friday, Nov. 8

268. Weight loss over time in the IKanEat pediatric tube weaning trial. 

269. Social determinant of healthcare engagement in the IKanEat pediatric tube weaning trial. 

305. Children with EoE can have frequent, multiple and variable symptoms: An analysis of baseline PESQ-C in the Phase 3 EOE Kids Trial. 

306. High concordance in reporting of signs and symptoms of EoE was observed between caregivers and patients with EoE ages 8 to 17. 

315. Who is the rarest of them all? Eosinophilic gastritis vs. collagenous gastritis. 

316. FLIP panometry in pediatric eosinophilic esophagitis (EoE) reflects fibro-stenotic disease but is highly influenced by anesthetic exposure.  

317. Impact of dupilumab on caregiver-reported signs of EoE, using PESQ-C over 52 weeks: Results from the Phase 2 EoE Kids Study. 

318. Effect of dupilumab on histologic, symptomatic and endoscopic outcomes in children with eosinophilic esophagitis, regardless of history of elimination diet or concomitant food allergy. 

361. Clinical benefits of maralixibat for patients with Alagille syndrome are durable through 7 years of treatment: Data from the Merge Study. 

368. A shared gene signature associated with TGFBI deficiency. 

373. A descriptive study of the very-early onset inflammatory bowel disease population with the ImproveCareNow Learning Health System. 

392. Hematuria due to secondary bladder wall inflammation as a presenting symptom of inflammatory bowel disease. 

408. Does quality of life and symptom severity correlate with celiac disease activity in adolescents? 

446. Diet manipulation and selective microbe editing ameliorates lethal enterocolitis in Hirschsprung disease. 

454. Increased goblet cell markers accompany RET-mediated aganglionosis in the neonatal colon. 

481. COVID-19 and its prolonged effect in shaping the hospitalization of patients with gastroparesis.  

482. COVID-19 pandemic and the healthcare economic burden imposed by gastroparesis admissions. 

497. Refeeding syndrome risk in a child with severe refractory ulcerative colitis and obesity. 

511. Parental stress and pediatric outpatient tube weaning: Insights from the IKanEat clinical trial. 

512. Changes in parent stress and mental health concerns throughout IKanEat pediatric tube weaning intervention. 

514. Paper, video or app for that: Caregiver preferences for receiving education on behavioral strategies for managing functional constipation with fecal incontinence. 

Concurrent Sessions IV: 10:30 a.m.-noon, Saturday, Nov. 9

543. Characteristics and clinical outcomes of children with autoimmune pancreatitis: A single tertiary care center experience. 

Poster Sessions III: Noon-2 p.m. Saturday, Nov. 9

554. A QI initiative to improve procedure prep calls in the GI endoscopy suite at CHOP. 

568. Gastroesophageal reflux disease and associated comorbidities in patients with 22q11.2 deletion syndrome. 

601. Safety of short-term therapy with budesonide oral suspension for eosinophilic esophagitis: An integrated analysis of adolescent safety data. 

605. Dupilumab with and without concomitant PPI at 16 and 52 weeks in children with eosinophilic esophagitis: Post-hoc analysis of the Phase 3 EoE Kids Study. 

623. Understanding community perspectives of pediatric tissue-based research in a rural setting.  

626. Improving programming to increase awareness of systemic inequities through needs assessment in pediatric gastroenterology. 

638. Improvements in pruritus after maralixibat treatment are associated with improved health-related quality of life for patients with cholestatic liver disease.  

692. Very early onset inflammatory bowel disease with NLRPI variant responsive to canakinumab. 

703. Gluten-free schooling: Navigating challenges and triumphs for children with celiac disease.  

717. Natural history of potential celiac disease in children. 

759. GLP-1 receptor agonists may improve pediatric metabolic dysfunction-associated steatotic liver disease independent of weight loss.  

Concurrent Sessions V: 2-3:30 p.m., Saturday, Nov. 9 

784. Topiramate: A possible therapeutic option for pediatric metabolic dysfunction-associated steatotic liver disease. 

Referral information

Referring a patient outside your care is an act of trust. You must be confident the team you refer to has the knowledge, training and experience to make a significant difference in the outcome for your patient. We’re here to assist you in providing the best care for your patients. To discuss a potential referral, schedule or seek a second opinion, please call 215-590-3630, option #2 or email CHOPRefGI@chop.edu.  

Learn what information you'll need to provide when referring a patient. 

Stay connected: Sign up for our newsletter

Sign up to get the latest news from the Division of Gastroenterology, Hepatology and Nutrition at Children's Hospital of Philadelphia (CHOP). Subscribe to our professional eNewsletter to receive updates on research and educational opportunities, resources for your patients, news about our clinical programs, and more.